Psoriatic Arthritis

In this Q&A, Krzysztof Bonek, MD, PhD, discussed the findings of his study that looked at the associations of IL-18 serum levels with serum lipids, cardiovascular risk and disease activity in patients with ankylosing spondylitis and psoriatic arthritis.

Shared insight on technical processes and protocols used to manage patients with psoriatic arthritis, including those for prescription fulfillment.

A brief overview on the drivers of noncompliance and treatment adherence in patients with psoriatic arthritis.

Rheumatology Network interviewed Jeffrey Stark, MD, to discuss the BE COMPLETE study, which examined the efficacy of bimekizumab for treating psoriatic arthritis.

The long-term success of any psoriatic arthritis treatment may be predictable as early as 3 months if a timely assessment and adjustment of disease management is prioritized.

“This dramatic change in healthcare delivery led to significant challenges amongst healthcare management teams, healthcare professionals as well as patients, especially during the early phases of implementation," investigators stated.

Expert perspectives on the importance of establishing good patient-provider relationships while managing psoriatic arthritis.

Reflections on the challenges inherent in managing psoriatic arthritis, particularly cost of care and educating patients on their disease.

On this month's episode of Overdrive, Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a network meta-analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Vibeke Strand, MD, shares that based on her data, secukinumab is an effective option for treating patients with psoriatic arthritis.

Experts delve into considerations regarding management of comorbidities in patients with psoriatic arthritis.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, talk about the importance of patient communication and the role of advanced practice clinicians.

Roy Fleishmann, MD, discusses his Rheumatology Winter Clinical Symposium presentation, “Beyond the package insert: JAK inhibitors (jakinibs): safety issues.”

Experts consider optimal treatment strategies for patients with treatment-resistant psoriatic arthritis.

An overview of treatment strategies and multimodality care essential to the management of psoriatic arthritis.

Up to 30% of patients with psoriasis eventually develop inflammatory synovio-entheseal (SE) inflammation.

Though psoriasis often precedes psoriatic arthritis, some studies have shown that the time to transition from psoriasis to PsA had not been fully explained by genetic factors alone.

Arthur Kavanaugh, MD, explains the recent developments in psoriatic arthritis and spondyloarthritis, as well as what rheumatologists should look forward to in 2022.

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

Shared insight on the role that nurse practitioners and advanced practice care providers have in the management of patients with psoriatic arthritis.

Experts review the pathophysiology of psoriatic arthritis and share their perspective on how it can impact patients and caregivers.

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

A panel of experts discuss the presentation of psoriatic arthritis and domains of disease.

John Tesser, MD; Nehad Soloman, MD; and Jennifer Simpson, DNP, review the pathophysiology of psoriatic arthritis.